So far, some monoclonal antibodies in CRSwNP have entered clinical application or clinical trial stage to treat nasal polyps, including omalizumab (anti‐IgE), reslizumab (anti‐IL‐5), mepolizumab (anti‐IL‐5) and dupilumab (anti‐IL‐4Rα).132. This evidence concerns the gene IL4R and nasal cavity polyp.